SoFi CEO enters prepaid forward contract on 1.5 million shares
CAMBRIDGE, MA - Moderna , Inc. (NASDAQ:MRNA) has secured a tender to supply its mRNA COVID-19 vaccine to the European Union, including additional countries Norway and North Macedonia. The agreement, announced today, allows 17 participating nations to procure Moderna's vaccine over the next four years.
Chantal Friebertshäuser, Moderna's Senior Vice President for Europe & Middle-East, emphasized the importance of diverse vaccine supply and the availability of pre-filled syringe formats. The latter is expected to streamline vaccination processes and reduce administration errors.
The European Commission authorized an updated version of Moderna's vaccine, Spikevax, in September 2024, which targets the SARS-CoV-2 variant JN.1. The approval extends to individuals aged six months and older.
Moderna, a pioneer in mRNA therapeutics and vaccines, has been at the forefront of mRNA technology, contributing significantly to the rapid development and production of COVID-19 vaccines. The company's mRNA platform is also being utilized to develop treatments for a range of other diseases.
This agreement marks a continuation of Moderna's commitment to supporting global health security through its innovative mRNA medicines. The information disclosed in this article is based on a press release statement from Moderna, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.